These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1167308)

  • 1. Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure.
    Harvengt C; Desager JP; Muschart JM; Tjandramaga YB; Verbeeck R; Verberckmoes R
    J Clin Pharmacol; 1975; 15(8-9):605-10. PubMed ID: 1167308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of practolol elimination in all grades of chronic renal failure.
    Kaye CM; Kumana CR; Franklin DA; Baker LR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):83-8. PubMed ID: 1165145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of practolol in chronic renal failure.
    Eastwood JB; Curtis JR; Smith RB
    Br Med J; 1973 Nov; 4(5888):320-2. PubMed ID: 4758423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency.
    Zazgornik J; Huang ML; Van Peer A; Woestenborghs R; Heykants J; Stephen A
    J Clin Pharmacol; 1993 Dec; 33(12):1214-8. PubMed ID: 7907347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
    Zazgornik J; Kuska J; Kokot F; Koch S; Van Peer A; Huang ML; Heykants J
    J Clin Pharmacol; 1991 Jul; 31(7):657-61. PubMed ID: 1910052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis].
    Aoki N; Kouda Y; Yoshikawa H; Usuda Y
    Jpn J Antibiot; 1995 Aug; 48(8):999-1002. PubMed ID: 7474327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of practolol in renal failure.
    Bodem G; Grieser H; Eichelbaum M; Gugler R
    Eur J Clin Pharmacol; 1974 Jul; 7(4):249-52. PubMed ID: 4853603
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis.
    Blum RA; Olson SC; Kohli RK; Horvath AM; Sedman AJ; Posvar EL
    J Clin Pharmacol; 1990 Oct; 30(10):938-42. PubMed ID: 2229454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
    Foote EF; Look ZM; Giles P; Keane WF; Halstenson CE
    Am J Kidney Dis; 1995 Mar; 25(3):420-5. PubMed ID: 7872319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
    Katsube T; Echols R; Arjona Ferreira JC; Krenz HK; Berg JK; Galloway C
    J Clin Pharmacol; 2017 May; 57(5):584-591. PubMed ID: 27874971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis.
    Marc-Aurele J; Caille G; Bourgoin J
    Sleep; 1987; 10 Suppl 1():22-6. PubMed ID: 3438644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin pharmacokinetics in patients with renal failure.
    Barendregt JN; Van Peer A; Van Der Hoeven JG; Van Oene JC; Tjandra YI
    Br J Clin Pharmacol; 1990 Jun; 29(6):715-23. PubMed ID: 2378791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure.
    Waaler A; Svaland M; Fauchald P; Jakobsen JA; Kolmannskog F; Berg KJ
    Nephron; 1990; 56(1):81-5. PubMed ID: 2234253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.